bluebird bio, Inc. (BLUE) NASDAQ

4.97

+0(+0.00%)

Updated at June 02 04:00PM

Currency In USD

bluebird bio, Inc.

Address

60 Binney Street

Cambridge, MA 02142

United States of America

Phone

339 499 9300

Sector

Healthcare

Industry

Biotechnology

Employees

248

First IPO Date

June 19, 2013

Key Executives

NameTitlePayYear Born
Mr. Andrew ObenshainPresident, Chief Executive Officer & Director746,6051975
Mr. Thomas J. KlimaChief Commercial & Operating Officer527,9241972
Mr. Joseph D. Vittiglio Esq., J.D.Chief Legal & Business Officer and Secretary574,4931972
Dr. Richard A. Colvin M.D., Ph.D.Chief Medical Officer691,4031967
Mr. Oliver James Sterling IIIChief Financial Officer & Principal Accounting Officer0N/A
Mr. Kasra KasraianSenior Vice President of Quality, Regulatory & CMC Sciences0N/A
Mr. Scott ShoemakerSenior Vice President of Technical Operations0N/A
Ms. Andrea WaltonChief People Officer0N/A

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.